In:
Dermatology, S. Karger AG, Vol. 233, No. 2-3 ( 2017), p. 164-169
Abstract:
〈 b 〉 〈 i 〉 Aims: 〈 /i 〉 〈 /b 〉 To analyse the correlation between serum human beta-defensin-2 (hBD-2) levels and response to JAK inhibitor in psoriasis. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 We evaluated the psoriasis area and severity index (PASI) and serum hBD-2 levels of 18 psoriasis patients randomized to receive placebo or tofacitinib 5 or 10 mg b.i.d. at baseline, week 8, and week 16. Serum hBD-2 levels were measured by enzyme-linked immunosorbent assay (ELISA). 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 The PASI achieved a dramatic reduction after tofacitinib 5 or 10 mg b.i.d. treatment for 16 weeks ( 〈 i 〉 p 〈 /i 〉 〈 0.05). Serum hBD-2 levels significantly decreased in patients treated with tofacitinib 10 mg b.i.d. compared with baseline and the placebo-treated patients ( 〈 i 〉 p 〈 /i 〉 〈 0.05). A significant correlation was found between hBD-2 levels and PASI ( 〈 i 〉 r 〈 /i 〉 = 0.52, 〈 i 〉 p 〈 /i 〉 〈 0.01). A serum hBD-2 level of 1,255.45 pg/mL was a cut-off between mild and moderate-to-severe psoriasis in ROC analysis. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 Serum hBD-2 level might be a possible biomarker for monitoring psoriasis treatment response and differentiating mild from moderate-to-severe psoriasis.
Type of Medium:
Online Resource
ISSN:
1018-8665
,
1421-9832
Language:
English
Publisher:
S. Karger AG
Publication Date:
2017
detail.hit.zdb_id:
1482189-8
Permalink